Jonathan Freimark
Education
M.P.A., economics, Princeton School of Public and International Affairs; B.A., international studies, American University School of International Service
Summary of Experience
Mr. Freimark specializes in the application of quantitative methods and data science tools to complex case work spanning health economics and outcomes research (HEOR), pharmaceuticals, and other areas. He also manages case teams in the firm’s HEOR, Epidemiology & Market Access and Data Science & Statistical Modeling practices. In his HEOR work, Mr. Freimark applies quantitative techniques to address questions related to patient outcomes, the economic burden of diseases, and cost-effectiveness analyses. He also has extensive experience designing and implementing advanced data analytics to support research into a range of disease areas, including oncology, autoimmune diseases, and genetic disorders. His data science work has included supporting the development of software tools to enable a pharmaceutical client to more efficiently build cross-indication economic models. Mr. Freimark’s research has been published in peer-reviewed journals and presented at clinical and economic conferences.
-
Epidemiology and economic burden of Von Hippel-Lindau Disease-associated central nervous system hemangioblastomas and pancreatic neuroendocrine tumors in the United States
Orphanet Journal of Rare Diseases, 2024
2024Jonasch E, Song Y, Freimark J, Berman R, Nguyen H, Signorovitch J, Sundaram M
-
Epidemiology and Economic Burden of Von Hippel-Lindau Disease-Associated Renal Cell Carcinoma in the United States
Clinical Genitourinary Cancer, 2023
2023Jonasch E, Song Y, Freimark J, Berman R, Nguyen H, Signorovitch J, Sundaram M
-
Functional and Clinical Outcomes Associated with Steroid Treatment among Non-Ambulatory Patients with Duchenne Muscular Dystrophy1
Journal of Neuromuscular Diseases, 2023
2023McDonald CM, Mayer OH, Hor KN, Miller D, Goemans N, Henricson EK, Marden JR, Freimark J, Lane H, Zhang A, Frean M, Trifillis P, Koladicz K, Signorovitch J
-
The Economic Burden of Recurrence in Triple-Negative Breast Cancer Among Working Age Patients in the United States
Advances in Therapy, 2022
2022Sieluk J, Song Y, Freimark J, Huang M, Haiderali A, Berman R, Wang T, Signorovitch J, Hirshfield KM
-
Impact of PASI response on work productivity and the effect of risankizumab on indirect costs using machine learning in patients with moderate-to-severe psoriasis
Journal of Dermatological Treatment, 2021
2021Lebwohl M, Soliman AM, Yang H, Wang J, Freimark J, Puig L
-
Post-transplant maintenance therapy in patients with FLT3-mutated acute myeloid leukemia: Real-world treatment patterns and outcomes
European Journal of Haematology, 2021
2021Griffin JD, Song Y, Yang H, Freimark J, Shah MV
-
A Commissioners’ History of Cartel Enforcement in Europe: Multidimensional Comparison of Administrations
Journal of European Competition Law & Practice, 2020
2020 -
Real-world outcomes of long-term prednisone and deflazacort use in patients with Duchenne muscular dystrophy: experience at a single, large care center
Journal of Comparative Effectiveness Research, 2020
2020Marden JR, Freimark J, Yao Z, Signorovitch J, Tian C, Wong BL
-
A Longitudinal Assessment of the Impact of Endometriosis on Patients' Salary Growth and Risk of Leaving the Workforce
Advances in Therapy, 2020
2020Estes SJ, Soliman AM, Yang H, Wang J, Freimark J